Anti-CIR1 monoclonal antibody

A hybrid approach is proposed to perform the locate and tracking a non-collaborative radio frequency emitter using ray tracing (RT) simulation tool, channel impulse response (CIR), and machine learning estimation. The technique can enhance communication intelligence (COMINT) systems or even perform the localization using a single sensor in an non-line-of-sight (NLOS) suburban scenario. A multipath fingerprint can identify the target position using the machine learning classification engine to perform the matching. Conventional localization techniques mitigate errors trying to avoid NLOS measurements in processing emitter position, while the multipath fingerprints proposed uses the reflection information to feed the pattern matching engine build on a machine learning classification framework. The methodwas applied to simulate a tactical scenario, where a navy frigate is in Ipanema and tries to track an RF emitter target in the Rio de Janeiro streets using only one RF sensors fixed in an aerostat in a hypothetical counterinsurgency situation.

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71 (8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was observed in 10/50 patients (20%) and 12 months cumulative incidence of relapse (CIR) was 23.6%. Median duration of response was not reached. In competing risk analysis, CIR was reduced when HSCT was performed in first CR (12 months CIR of 5% and 37.4%, respectively, for patients receiving (=20) or not (=30) HSCT,p = 0.012). Twelve-months OS was 68.6% (median not reached). In landmark analysis, HSCT in CR1 was the only significant predictor of longer survival (12 months OS of 100 and 70.5%, for patients undergoing or not HSCT in CR1, respectively,p = 0.011). In conclusion, we extend to a real-life setting, the notion that CPX is an effective regimen for high risk AML patients and may improve the results of HSCT.